Skip to Content
Merck
  • Endogenous topoisomerase II-mediated DNA breaks drive thymic cancer predisposition linked to ATM deficiency.

Endogenous topoisomerase II-mediated DNA breaks drive thymic cancer predisposition linked to ATM deficiency.

Nature communications (2020-02-16)
Alejandro Álvarez-Quilón, José Terrón-Bautista, Irene Delgado-Sainz, Almudena Serrano-Benítez, Rocío Romero-Granados, Pedro Manuel Martínez-García, Silvia Jimeno-González, Cristina Bernal-Lozano, Cristina Quintero, Lourdes García-Quintanilla, Felipe Cortés-Ledesma
ABSTRACT

The ATM kinase is a master regulator of the DNA damage response to double-strand breaks (DSBs) and a well-established tumour suppressor whose loss is the cause of the neurodegenerative and cancer-prone syndrome Ataxia-Telangiectasia (A-T). A-T patients and Atm-/- mouse models are particularly predisposed to develop lymphoid cancers derived from deficient repair of RAG-induced DSBs during V(D)J recombination. Here, we unexpectedly find that specifically disturbing the repair of DSBs produced by DNA topoisomerase II (TOP2) by genetically removing the highly specialised repair enzyme TDP2 increases the incidence of thymic tumours in Atm-/- mice. Furthermore, we find that TOP2 strongly colocalizes with RAG, both genome-wide and at V(D)J recombination sites, resulting in an increased endogenous chromosomal fragility of these regions. Thus, our findings demonstrate a strong causal relationship between endogenous TOP2-induced DSBs and cancer development, confirming these lesions as major drivers of ATM-deficient lymphoid malignancies, and potentially other conditions and cancer types.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
SIGMAFAST 3,3′-Diaminobenzidine tablets, tablet, To prepare 15 mL
Sigma-Aldrich
N-Lauroylsarcosine sodium salt solution, 20%, for molecular biology